Home Contact  

   QuatRx Pharmaceuticals

   is a pharmaceutical
   company focused on
   compounds in the
   endocrine and metabolic
   therapeutic areas.

OsphenaTM (ospemifene)

Our most advanced product, ospemifene, received FDA approval in February 2013 for the treatment of moderate to severe dyspareunia (painful sexual intercourse), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. It was launched in May 2013 by our partner Shionogi Inc. under the trade name OsphenaTM.

For more information see www.Osphena.com


Other Programs

QuatRx Pharmaceuticals has now divested all other clinical and pre-clinical programs in its portfolio to Forendo Pharma, based in Turku, Finland.

For more information see www.Forendo.com


© 2013 QuatRx Pharmaceuticals CompanyTerms of Use